Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure

Abstract Elevated fibroblast growth factor 23 (FGF23) levels are associated with adverse outcome in populations with cardiovascular disease and chronic kidney failure. It is unclear if FGF23 has significance in prognosis estimation in patients with acute heart failure (HF) when compared to tradition...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne Cornelissen, Roberta Florescu, Kinan Kneizeh, Christian Cornelissen, Vincent Brandenburg, Elisa Liehn, Alexander Schuh
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3e4cc40fbeaf43d49258d67aa709c569
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e4cc40fbeaf43d49258d67aa709c569
record_format	dspace
spelling	oai:doaj.org-article:3e4cc40fbeaf43d49258d67aa709c5692021-12-02T16:06:44ZIntact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure10.1038/s41598-021-94780-72045-2322https://doaj.org/article/3e4cc40fbeaf43d49258d67aa709c5692021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94780-7https://doaj.org/toc/2045-2322Abstract Elevated fibroblast growth factor 23 (FGF23) levels are associated with adverse outcome in populations with cardiovascular disease and chronic kidney failure. It is unclear if FGF23 has significance in prognosis estimation in patients with acute heart failure (HF) when compared to traditional risk estimation tools. Serum levels of intact FGF23 were assessed in 139 patients admitted to the Intermediate Care Unit of a tertiary hospital for acute HF. Patients were followed-up for one year. After exclusion of patients who were lost to follow-up, data outliers, and patients with sampling errors, the final study cohort comprised 133 patients. The Seattle Heart Failure (SHF) Model was used to estimate one-year survival. FGF23 levels correlated with HF severity and were strongly associated with one-year mortality. Associations between one-year outcome and FGF23, assessed on day 1 after admission, were still evident after multivariable adjustment (OR 15.07; 95%CI 1.75–129.79; p = 0.014). FGF23 levels predicted the one-year outcome with similar accuracy as the SHF Model, both if assessed on day 1 and on day 2 after admission (FGF23d1: AUC 0.784; 95%CI 0.669–0.899; FGF23d2: AUC 0.766; 95%CI 0.631–0.901; SHF: AUC 0.771; 95%CI 0.651–0.891). The assessment of FGF23 in patients with acute HF might help identify high-risk patients that are more prone to complications, need a closer follow-up and more aggressive treatment.Anne CornelissenRoberta FlorescuKinan KneizehChristian CornelissenVincent BrandenburgElisa LiehnAlexander SchuhNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Anne Cornelissen Roberta Florescu Kinan Kneizeh Christian Cornelissen Vincent Brandenburg Elisa Liehn Alexander Schuh Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure
description	Abstract Elevated fibroblast growth factor 23 (FGF23) levels are associated with adverse outcome in populations with cardiovascular disease and chronic kidney failure. It is unclear if FGF23 has significance in prognosis estimation in patients with acute heart failure (HF) when compared to traditional risk estimation tools. Serum levels of intact FGF23 were assessed in 139 patients admitted to the Intermediate Care Unit of a tertiary hospital for acute HF. Patients were followed-up for one year. After exclusion of patients who were lost to follow-up, data outliers, and patients with sampling errors, the final study cohort comprised 133 patients. The Seattle Heart Failure (SHF) Model was used to estimate one-year survival. FGF23 levels correlated with HF severity and were strongly associated with one-year mortality. Associations between one-year outcome and FGF23, assessed on day 1 after admission, were still evident after multivariable adjustment (OR 15.07; 95%CI 1.75–129.79; p = 0.014). FGF23 levels predicted the one-year outcome with similar accuracy as the SHF Model, both if assessed on day 1 and on day 2 after admission (FGF23d1: AUC 0.784; 95%CI 0.669–0.899; FGF23d2: AUC 0.766; 95%CI 0.631–0.901; SHF: AUC 0.771; 95%CI 0.651–0.891). The assessment of FGF23 in patients with acute HF might help identify high-risk patients that are more prone to complications, need a closer follow-up and more aggressive treatment.
format	article
author	Anne Cornelissen Roberta Florescu Kinan Kneizeh Christian Cornelissen Vincent Brandenburg Elisa Liehn Alexander Schuh
author_facet	Anne Cornelissen Roberta Florescu Kinan Kneizeh Christian Cornelissen Vincent Brandenburg Elisa Liehn Alexander Schuh
author_sort	Anne Cornelissen
title	Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure
title_short	Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure
title_full	Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure
title_fullStr	Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure
title_full_unstemmed	Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure
title_sort	intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3e4cc40fbeaf43d49258d67aa709c569
work_keys_str_mv	AT annecornelissen intactfibroblastgrowthfactor23levelsandoutcomepredictioninpatientswithacuteheartfailure AT robertaflorescu intactfibroblastgrowthfactor23levelsandoutcomepredictioninpatientswithacuteheartfailure AT kinankneizeh intactfibroblastgrowthfactor23levelsandoutcomepredictioninpatientswithacuteheartfailure AT christiancornelissen intactfibroblastgrowthfactor23levelsandoutcomepredictioninpatientswithacuteheartfailure AT vincentbrandenburg intactfibroblastgrowthfactor23levelsandoutcomepredictioninpatientswithacuteheartfailure AT elisaliehn intactfibroblastgrowthfactor23levelsandoutcomepredictioninpatientswithacuteheartfailure AT alexanderschuh intactfibroblastgrowthfactor23levelsandoutcomepredictioninpatientswithacuteheartfailure
_version_	1718384898337669120

Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure

Ejemplares similares